Darzalex Delays Disease Progression After ASCT, Phase 3 Trial Reports
First-line maintenance therapy with Darzalex (daratumumab) significantly delays disease progression…
Myeloma
Myeloma overview
Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
Read moreMyeloma treatment
While myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
Read moreLatest news
Oncopeptides Will Seek Conditional Approval of Melflufen in Europe
Oncopeptides soon will seek conditional approval of…
Sarclisa Triple Combo Conditionally Approved for NHS Use in England, Wales
After first rejecting a Sarclisa (isatuximab) triple combination therapy…
1st Patient Dosed With Investigational T-cell Therapy NEXI-002 in Phase 1/2 Trial
NexImmune has dosed the first patient participating in…
Glycostem’s oNKord Cell-based Therapy Granted FDA Orphan Drug Designation
The U.S. Food and Drug Administration (FDA) has…
Cytovia, Inserm Partnering on NK-based Immunotherapies for Myeloma
A recent collaboration between Cytovia Therapeutics and Inserm,…
